Nephrotoxicities of nonsteroidal anti-inflammatory drugs

Journal of the Formosan Medical Association

Volumn 96, Issue 3, 1997, Pages 157-171

  Wen, Sung Feng ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

nonsteroidal anti inflammatory drugs; prostaglandins; renal toxicity

Indexed keywords

ACETYLSALICYLIC ACID; BENORILATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARPROFEN; DICLOFENAC; DIFLUNISAL; DIURETIC AGENT; ETODOLAC; FENOPROFEN; FENOPROFEN CALCIUM; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; OXYPHENBUTAZONE; PHENYLBUTAZONE; PIRPROFEN; PROSTAGLANDIN; SALICYLAMIDE; SALICYLIC ACID; SALSALATE; SULINDAC; SUPROFEN; TOLMETIN; UNINDEXED DRUG; ZOMEPIRAC;

DRUG EFFECT; DRUG TOXICITY; DRUG WITHDRAWAL; HEMODYNAMICS; HUMAN; HYPERTENSION; NEPHROTOXICITY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; PROSTAGLANDINS;

EID: 0030899145     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Cronin RE, Henrich WL: Toxin nephropathy: nonsteroidal anti-inflammatory drugs. In: Brenner GM, ed. The Kidney. 5th ed. Philadelphia: WB Saunders, 1996:1696-711.
2. Roth SH, Bennett RE: Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987;147:2093-100.
3. Lewis JH: Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharmacol 1984;3:128-38.
4. Clive DM, Stoff JS: Renal syndromes associated with anti-inflammatory drugs. New Engl J Med 1984;310:563-72.
5. Blackshear JL, Napier JS, Davidman M, et al: Renal complications of non-steroidal anti-inflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985;14:163-75.
6. Kleinknecht D, Landais P, Goldfarb B: Analgesic and non-steroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol 1986;25:275-81.
7. Pirson Y, van Ypersele de Strihou C: Renal side effects of nonsteroidal anti-inflammatory drugs: clinical relevance. Am J Kidney Dis 1986;8:338-44.
8. Segasothy M, Samad S, Zulfigar A, et al: Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesics. Am J Kidney Dis 1994;24:17-24.
9. Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. New Engl J Med 1994;331:1675-9.
10. 2 in cultured rat mesangial cells. Am J Physiol 1987;253:C113-20.
11. Zusman RM, Keiser HR: Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture: stimulation by angiotensin II, bradykinin and vasopressin. J Clin Invest 1977;60:215-23.
12. Levine L, Moskowitz MA: Alpha and beta adrenergic stimulation of arachidonic acid metabolism in cells in culture. Proc Natl Acad Sci USA 1979;76:6632-6.
13. McGiff JC, Crowshaw K, Terragno NA, et al: Differential effect of noradrenaline and renal nerve stimulation on vascular resistance in the dog kidney and the release of a prostaglandin E-like substance. Clin Sci 1972;42:223-33.
14. Dunn MJ, Hood VL: Prostaglandins and the kidney. Am J Physiol 1977;233:F169-84.
15. Hong SL, Levine L: Stimulation of prostaglandin synthesis by bradykinin and thrombin and their mechanisms of action on MC5-5 fibroblasts. J Biol Chem 1976:5814-6.
16. Hong SL, Levine L: Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci USA 1976;73:1730-4.
17. Egan RW, Paxton J, Kuehl FA Jr: Mechanism for irreversible self-deactivation of prostaglandin synthetase. J Biol Chem 1976;251:7329-35.
18. Simon LS, Mills JA: Nonsteroidal anti-inflammatory drugs. New Engl J Med 1980;302:1179-85.
19. Hirt DL, Jacobson HR: Functional effects of cytochrome P450 arachidonate metabolites in the kidney. Semin Nephrol 1991;11:148-55.
20. 1 on glomerular dynamics in the rat. Am J Physiol 1987;253:F239-43.
21. 1 in the porcine renal vascular bed. Prostaglandins 1985;29:61-73.
22. 1 in normal and glomerulonephritis kidneys. J Am Soc Nephrol 1991;2:45-56.
23. Garella A, Matarese RA: Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine (Baltimore) 1984;63:165-81.
24. Ruilope LM, Robles RG, Paya C, et al: Effects of long-term treatment with indomethacin on renal function Hypertension 1986;8:677-84.
25. Schnermann J, Briggs JP, Weber PC: Tubuloglomerular feedback, prostaglandins, and angiotensin in the autoregulation of glomerular filtration rate. Kidney Int 1984;25:53-64.
26. Yared A, Kon V, Ichikawa I: Mechanisms of preservation of glomerular perfusion and filtration during acute extracellular volume depletion: importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. J Clin Invest 1985;75:1477-87.
27. Conger JD: Endothelial regulation of vascular tone. Hosp Pract 1994;29:117-26.
28. Schramek H, Coroncos E, Dunn MJ: Interactions of the vasoconstrictor peptides, angiotensin II and endothelin-1, with vasodilatory prostaglandins. Semin Nephrol 1995;15:195-204.
29. 1a formation by isolated human glomeruli. Kidney Int 1984;26:30-4.
30. Scharschmidt LA, Dunn MJ: Prostaglandin synthesis by rat glomerular mesangial cells in culture: effects of angiotensin II and arginine vasopressin. J Clin Invest 1983;71:1756-64.
31. Hura CE, Kunau RT Jr: Angiotensin II-stimulated prostaglandin production by canine renal afferent arterioles. Am J Physiol 1988;254:F734-8.
32. Rose BD: Clinical Physiology of Acid-base and Electrolyte Disorders. 4th ed. New York: McGraw-Hill, 1994:31-3.
33. Blantz RC, Konnen KS, Tucker BJ: Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57:419-34.
34. Johnson GR, Wen SF: Syndrome of flank pain and acute renal failure after binge drinking and nonsteroidal anti-inflammatory drug ingestion. J Am Soc Nephrol 1995;5:1647-52.
35. Myers BD, Deen WM, Brenner BM: Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal fluid reabsorption in the rat. Circ Res 1975;37:101-10.
36. Edwards RM: Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol 1985;F779-84.
37. Henrich WL: Nephrotoxicity of nonsteroidal anti-inflammatory agents. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. 5th ed. Boston: Little, Brown and Company, 1993:1203-17.
38. Nadler SP, Brenner GM: Role of arachidonic acid metabolites in body fluid homeostasis. In: Brenner GM, Stein JH, eds. Contemporary Issues in Nephrology 16: Body Fluid Homeostasis. New York: Churchill Livingstone, 1987:101-29.
39. 2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977;59:1099-104.
40. Roman RJ, Kauker ML: Renal effect of prostaglandin synthetase inhibition in rats: micropuncture studies. Am J Physiol 1978;235:F111-8.
41. Work J, Baehler TR, Kotchen A, et al: Effect of prostaglandin inhibition on sodium chloride reabsorption in the diluting segment of the conscious dog. Kidney Int 1980;17:24-30.
42. Wilson DR, Honrath U, Sonnenberg H: Prostaglandin synthesis inhibition during volume expansion: collecting duct function. Kidney Int 1982;22:1-7.
43. Carmines PK, Bell PD, Roman RJ, et al: Prostaglandins in the sodium excretory response to altered renal arterial pressure in dogs. Am J Physiol 1985;248:F8-14.
44. Epstein M, Lifschitz MD, Hoffman DS, et al: Relationship between renal prostaglandin E and renal sodium handling during water immersion in normal man. Circ Res 1979;45:71-80.
45. Tweeddale MG, Ogilvie RI: Antagonism of spironolactone-induced natriuresis by aspirin in man. New Engl J Med 1973;289:198-200.
46. Attallah AA: Interaction of prostaglandins with diuretics. Prostaglandins 1979;18:369-75
47. Favre L, Glasson PH, Riondel A, et al: Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clin Sci 1983;64:407-15.
48. Tiggeler RG, Koene RA, Wijdeveld PG: Inhibition of furosemide-induced natriuresis by indomethacin in patients with nephrotic syndrome. Clin Sci Mol Med 1977;52:149-51.
49. Feldman D, Couropmitree C: Intrinsic mineralocorticoid agonist activity of some non-steroidal anti-inflammatory drugs. J Clin Invest 1976;57:1-7.
50. Nies AS, Gal J, Fadul S, et al: Indomethacin-furosemide interaction: the importance of renal blood flow. J Pharmacol Exp Ther 1983;226:27-32.
51. Dunn MJ: Renal prostaglandins: influence on excretion of sodium and water, the renin-angiotensin system, renal blood flow, and hypertension. In: Brenner BM, Stein JH, eds. Contemporary Issues in Nephrology 4: Hormonal Function and the Kidney. New York: Churchill Livingstone, 1979:89-114.
52. 1 on the permeability response of the isolated collecting tubule to vasopressin, adenosine 3′,5′-monophosphate and theophylline. J Clin Invest 1968;47:1154-61.
53. Gross PA, Schrier RW, Anderson RJ: Prostaglandins and water metabolism: a review with emphasis on in vivo studies. Kidney Int 1981;19:839-50.
54. Stokes JB: Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981;240:F471-80.
55. Henrich WL, Camphell WB: Importance of intracellular calcium in tissue renin release. Clin Res 1982;32:242A.
56. 1-adrenoreceptors and prostaglandins in reflex renin release. Am J Physiol 1983;244:F418-24.
57. Ito S, Carretero OA, Abe K, et al: Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int 1989;35:1138-44.
58. Henrich WL, Campbell WB: Relationship between prostaglandins and the β-adrenergic pathway to renin secretion: an in vitro study. Am J Physiol 1984;247:E343-8.
59. Tan SY, Shapiro R, Franco R, et al: Indomethacin-induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979;90:783-5.
60. Henrich WL, Agodoa LE, Barnett B, et al: Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-5.
61. Buckalew VM Jr, Schey H: Renal disease from habitual antipyretic analgesic consumption: an assessment from the epidemiologic evidence. Medicine (Baltimore) 1986;65:291-303.
62. Nanra RS, Stuart-Taylor JM, deLeon AH, et al: Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978;13:79-92.
63. Bennett WM, DeBroe ME: Analgesic nephropathy: a preventable renal disease. New Engl J Med 1989;320: 1269-71.
64. Noels LM, Elseviers MM, DeBroe ME: Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study of France, Sweden, and Belgium. Nephrol Dial Transplant 1995;10:167-74.
65. Elseviers MM, DeBroe ME: Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol Dial Transplant 1994;9:41-6.
66. Davenport A, Finn R: Paracetamol (acetaminophen) poisoning resulting in acute renal failure without hepatic coma. Nephron 1988;50:55-6.
67. Sandler DP, Smith JC, Weinberg CR, et al: Analgesic abuse and chronic renal disease. New Engl J Med 1989;320:1238-43.
68. Segasothy M, Suleiman AB, Puvaneswarv M, et al: Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 1988;50:50-4.
69. Johnson JH, Jick H, Hunter JR, et al: A follow-up study of ibuprofen users. J Rheumatol 1985;12:549-52.
70. Bonney SL, Northington RS, Hedrich DA, et al: Renal safety of two analgesics used over the counter: ibuprofen and aspirin. Clin Pharmacol Ther 1986;40:373-7.
71. Murray MD, Brater PC, Tierney WM, et al: Ibuprofen-associated renal impairment in a large general internal medicine practice. Am J Med Sci 1990;299:222-9.
72. Corwin HL, Bonventre JV: Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am J Kidney Dis 1984;4:147-52.
73. Kleinknecht D: Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:228-35.
74. Ciabattoni G, Cinotti GA, Pierucci A, et al: Effects of sulindac and ibuprofen in patients with chronic glomerular disease: evidence for the dependence of renal function on prostacyclin. New Engl J Med 1984;310:279-83.
75. Henrich WL, Brater DC, Campbell WB: Sulindac accentuates renal ischemia during hemorrhage. Kidney Int 1985;27:295. [Abstract]
76. Champion de Crespigny PJ, Becker CJ, Ihle BU, et al: Renal failure and nephrotic syndrome associated with sulindac. Clin Nephrol 1988;30:52-5.
77. Swainson CP, Griffiths P, Watson ML: Chronic effects of oral sulindac on renal hemodynamics and hormones in patients with chronic renal disease. Clin Sci 1986,70:243-7.
78. DeWitt DL, Meade EA, Smith WL: PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993;95:40s-44s.
79. Porro GB, Montrone F, Petrillo M, et al: Gastrointestinal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995;90:1485-8.
80. Lancaster C: Effective nonsteroidal anti-inflammatory drugs devoid of gastrointestinal side effects: do they really exist? Dig Dis 1995;13:40-7.
81. DeCaterina R, Giannessi D, Lazzerini G, et al: Effect of nabumetone on metabolism of renal arachidonate in humans. J Rheumatol 1992;19:80.
82. Aronoff GR: Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992;19:25-31.
83. Hart D, Ward M, Lifschitz MD: Suprofen-related nephrotoxicity: a distinct clinical syndrome. Ann Intern Med 1987;106:235-8.
84. Rossi AC, Bosco L, Faich GA: The importance of adverse reaction reporting by physicians: Suprofen and the flank pain syndrome. J Am Med Assoc 1988;259:1203-4.
85. Blackshear JL, Davidman M, Stillman MT: Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs. Arch Intern Med 1983;143:1130-4.
86. Favre L, Glasson P, Vallotton MB: Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med 1982;96-317-20.
87. Blau EB: Ibuprofen and ethanol overdose-induced acute tubular necrosis. Wis Med J 1987;86:23-4.
88. Elsasser GN, Lopez L, Evans E, et al: Reversible acute renal failure associated with ibuprofen ingestion and binge drinking. J Fam Pract 1988;27:221-2.
89. Wen SF, Parthasarathy R, Iliopoulos O, et al: Acute renal failure following binge drinking and nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1992;20:281-5.
90. Palmer BF, Henrich WL: Clinical acute renal failure with nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995;15:214-27.
91. Galler M, Folkert VW, Schlondorf D: Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. J Am Med Assoc 1981;246:154-5.
92. Walshe JJ, Venuto RC: Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979;91:47-9.
93. Brater DC, Anderson SA, Brown-Cartwright D: Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci 1987;294:168-74.
94. Zisper RD, Hoefs JC, Spechart PF, et al: Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895-900.
95. Arisz L, Douker AJM, Brentjens JRH, et al: The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976;199: 121-5.
96. Whelton A, Stout RL, Spilman PS, et al: Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med 1990;112:568-76.
97. Kimberly RP, Plotz PH: Aspirin-induced depression of renal function. New Engl J Med 1977;296:418-24.
98. Fong JH, Cohen AH: Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982;2:28-31.
99. Bridoux F, Hazzan M, Pallot JL, et al: Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992;7:100-4.
100. Carmichael J, Shankel SW: Effects of non-steroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 1985;78:992-1000.
101. Kimberly RP, Bowden RE, Keiser HR, et al: Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med 1978;64:804-7.
102. Antillon M, Cominelli F, Lo S, et al: Effects of oral prostaglandins on indomethacin-induced renal failure in patients with cirrhosis and ascites. J Rheumatol Suppl 1990;20:46-9.
103. Brezin J, Katz S, Schwartz A, et al: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 1979;301:1271-3.
104. Abraham PA, Keane WF: Glomerular and interstitial disease induced by non-steroidal anti-inflammatory drugs. Am J Nephrol 1984;4:1-6.
105. Ditlove J, Weidman P, Berstein M, et al: Methicillin nephritis. Medicine (Baltimore) 1977;56:483-91.
106. Lofgren R, Nelson A, Ehler S: Fenoprofen-induced acute interstitial nephritis presenting with nephrotic syndrome. Minn Med 1981;64:287-90.
107. Bender WL, Whelton A, Beschorner WE, et al: Interstitial nephritis, proteinuria and renal failure caused by non-steroidal anti-inflammatory drugs: immunological characterization of the infiltrate. Am J Med 1984;76:1006-12.
108. Finklestein A, Fralev D, Stachura I, et al: Fenoprofen nephropathy: lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder. Am J Med 1982;72:81-7.
109. Sobel A, Heslan JM, Branellec A, et al: Vascular permeability factor produced by lymphocytes of patients with nephrotic syndrome. Adv Nephrol Necker Hosp 1981;10:315-32.
110. Torres VE: Present and future of non-steroidal anti-inflammatory drugs in nephrology. Mayo Clin Proc 1982;57:390-3.
111. Goetzl EJ: Mediators of immediate hypersensitivity derived from arachidonic acid. New Engl J Med 1980;303:822-5.
112. Adams DH, Adu D: Non-steroidal anti-inflammatory drugs and the kidney. In: Cameron S, Davison AM, Grunnfeld JP, et al, eds. Oxford Textbook of Clinical Nephrology. Oxford: Oxford University Press, 1992:819-25.
113. Morgenstern SJ, Bruns FS, Fraley DS, et al: Ibuprofen-associated lipoid nephrosis without interstitial nephritis. Am J Kidney Dis 1989;16:50-2.
114. Cameron JS: Allergic interstitial nephritis: clinical features and pathogenesis. Quart J Med 1988;66:97-115.
115. Adams DH, Howie AJ, Michael J, et al: Non-steroidal anti-inflammatory drugs and renal failure. Lancet 1986;1:57-60.
116. Ter Borg EJ, de Jonge PE, Meyer S, et al: Indomethacin and ibuprofen-induced reversible acute renal failure in a patient with systemic lupus en thematosus. Neth J Med 1987;30:181-6.
117. Ling BN, Bourke E, Campbell WG: Naproxen-induced nephropathy in systemic lupus erythematosus. Nephron 1990;54:249-55.
118. Kirschenbaum MA, White N, Stein JH, et al: Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis Am J Physiol 1974;227:801-5.
119. Nanra RS, Chirawong P, Kincaid-Smith P: Medullary ischemia in experimental analgesic nephropathy: the pathogenesis of renal papillary necrosis. Aust NZ J Med 1973;3:580-6.
120. Mihatsch MJ, Hofer HO, Gudat F, et al: Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983;20:285-301.
121. Eknoyan G: Analgesic nephrotoxicity and renal papillary necrosis. Semin Nephrol 1984;4:65-76.
122. Davis BB, Mattammal MB, Zenser TV: Renal metabolism of drugs and xenobiotics. Nephron 1981;27:187-96.
123. Munn E, Lynn KL, Bailey RR: Renal papillary necrosis following regular consumption of non-steroidal anti-inflammatory drugs. N Z Med J 1982;95:213-4.
124. Wiseman EH, Reinert H: Anti-inflammatory drugs and renal papillary necrosis. Agents Actions 1975;5:322-5.
125. Husserl FE, Lange RK, Kanthrow CM Jr: Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. J Am Med Assoc 1979;242:1896-8.
126. Robertson CE, Van Someren V, Ford MJ, et al: Mefenamic acid nephropathy. Lancet 1980;2:232-3.
127. Robbins SL, Mallory GK, Kinney DT: Necrotizing renal papillitis: form of acute pyelonephritis New Engl J Med 1946;235:885-93.
128. Eknoyan G, Quinibi WY, Grisson RT, et al: Renal papillary necrosis: an update. Medicine (Baltimore) 1982;61:55-73.
129. Kincaid-Smith P: Analgesic abuse and the kidney. Kidney Int 1980;17:250-60.
130. Ellis PS, Pollack HM: The radiologie manifestations of renal papillary necrosis. Semin Nephrol 1984;4:77-87.
131. Goebal KM, Muellar-Brodmann, W: Reversible overt nephropathy with Henoch-Schönlem purpura due to piroxicam. Br Med J 1982;284:311-2.
132. Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983;23:647-55.
133. Kuncio GS, Neilson EG, Haverty T: Mechanisms of tubulointerstitial fibrosis. Kidney Int 1991;39:550-6.
134. Mirouze D, Zisper RD, Reynolds TB: Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983;3:50-5.
135. Berg KJ: Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency. Eur J Clin Pharmacol 1977;11:111-6.
136. Patak RY, Mookerjee BK, Bentzel CJ, et al: Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 1975;10:649-59.
137. Szylman P, Better OS, Chaimowitz C, et al: Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. New Engl J Med 1975;294:361-5.
138. DeFronzo RA: Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980;17:118-34.
139. Nadler JL, Lee FO, Hsueh W, et al: Evidence of prostacyclin deficiency in the syndrome of hyporeninemic hypoaldosteronism. New Engl J Med 1986;314:1015-20.
140. Norby LH, Weidig J, Ramwell P, et al: Possible role for impaired renal prostaglandin production in pathogenesis of hyporeninaemic hypoaldosteronism. Lancet 1978;2:1118-22.
141. Gill JR Jr, Frolich JC, Bowden RE, et al: Banter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 1976;61:43-51.
142. Verberckmoes R, VanDamme B, Clement J, et al: Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 1976;9:302-7.
143. Houston MC: Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991;90(suppl 5A): 42s-47s.
144. Beckmann ML, Gerber JG, Byyny RL, et al: Propranolol increases prostacyclin synthesis in patients with hypertension. Hypertension 1988;12:582-8.
145. Negus P, Tannen RL, Dunn MJ: Indomethacin potentiates the vasoconstrictor actions of angiotensin II. Prostaglandins 1976;12:175-80.
146. Luscher TF: Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension? Am J Hypertens 1990;3:317-30.
147. Mene P, Pugliese F, Patrono C: The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 1995;15: 244-52.
148. Wong DG, Lamki L, Spence JD, et al: Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986;1:997-1001.
149. Watkins J, Abbott EC, Hensby CN: Attenuation of the hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J 1980;281:702-5.
150. Yitalo P, Pitkajarvi T, Nurmi AK, et al: Inhibition of prostaglandin synthesis by indomethacin interacts with antihypertensive effect of atenolol. Clin Pharmacol Ther 1985;38:443-9.
151. Rubin P, Jackson G, Blaschke T: Studies on the clinical pharmacology of prazosin. II: The influence of indomethacin and of propranolol on the action and disposition of prazosin. Br J Clin Pharmacol 1980;10:33-9.
152. Moore TJ, Crantz FR, Hollenberg NK, et al: Contribution of prostaglandins to the anti-hypertensive action of captopril in essential hypertension. Hypertension 1981;3:168-73.
153. Seelig CB, Maloley PA, Campbell JR: Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J 1990;83:1144-8.
154. Berg KJ, Forre O, Djoseland O, et al: Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis. Clin Nephrol 1989;31:232-8.
155. Remuzzi A, Remuzzi G: The effects of nonsteroidal anti-inflammatory drugs on glomerular filtration of proteins and their therapeutic utility. Semin Nephrol 1995;15:236-43.